tweetindex
FR

Muthu Vaduganathan

@mvaduganathan

Cardiologist & Trialist @BrighamWomens @harvardmed | AE @JACCJournals | Podcast #DontMissABeat & #HFinFocus | Disclosures: https://t.co/BmQHCNyLml

9 583Followers
506Following
7 466Posts total
112.5KViews on collected posts

Derniers posts

@mvaduganathan @AndrewJSauer Unexpected indeed 194 views · 0 likes · 0 reposts · 0 replies Open on X →
@mvaduganathan Not unexpected to those who watched for years. 394 views · 1 likes · 0 reposts · 1 replies Open on X →
@mvaduganathan simva40 for primary prevention, Atorva40 for secondary. Thats all you need to remember abo zur Lipids. Everything else is evidence free bullshit zone. 349 views · 0 likes · 0 reposts · 0 replies Open on X →
Wow! Unexpectedly, #LpaHORIZON P3 global CVOT of pelacarsen (ASO) does not show reduction in 4-point MACE in 8,323 patients with elevated Lp(a) and established CVD. https://t.co/JNRApyUYAB https://t.co/0pD3cekWlI
11.6K views · 125 likes · 28 reposts · 7 replies Open on X →
@mvaduganathan It's a wonderful drug All those trials to be interpreted in between All lost the significance by a margin I feel to be pharmacy driven Only issue is gynaecomazia hyperkalemia ( the latter is also common with eplerenone) 167 views · 1 likes · 0 reposts · 0 replies Open on X →
@mvaduganathan Ahi! Thank you Muthu! And thank you for the time you spent for evidence ! 646 views · 3 likes · 0 reposts · 0 replies Open on X →
@mvaduganathan lol. only talking about HF. TOPCAT in my view was positive trial due to fishiness in certain regions. SPIRITHF is harder to reconcile since stopped early. CKD is not really a disease and the outcomes from the trials don't necessarily translate to living better or l 19.3K views · 19 likes · 0 reposts · 9 replies Open on X →
Spironolactone Outcomes RCTs in the Last 20y #TOPCAT (HFpEF) ❓❌ #SPIRITHF (HFpEF) ❓❌ #CLEAR (Post-MI) ❌ #BARACKD (CKD) ❌ #ALCHEMIST (ESKD) ❌ #ACHIEVE (ESKD) ❌ One day we will hopefully have a positive RCT to elevate eminence based medicine to evidence based medicine! 40.3K views · 146 likes · 34 reposts · 11 replies Open on X →
agree. spironolactone IMO does the same thing. no head to head trial. doubtful will ever be done 39.5K views · 14 likes · 0 reposts · 0 replies Open on X →

Face aux comptes de taille comparable

9 posts des 90 derniers jours, à côté de la tranche de under 10K abonnés. en dessous de ses pairs à la fois en portée et en engagement.

Vues médianes646ce compte4 175médiane pour under 10K
Portée, %6.74%ce compte250.82%médiane pour under 10K
Engagement, %0.46%ce compte1.41%médiane pour under 10K
IndicateurCe compteMédiane pour under 10KRapport
Vues médianes par post6464 1750.15×
Portée (vues ÷ abonnés)6.74%2.5× audience0.03×
Taux d'engagement0.46%1.41%0.33×

Autres comptes de cette tranche →   Comparer avec un autre compte →   Comment ces repères sont établis →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

39.5K2 Sep
40.3K
19.3K
646
1673 Sep
11.6K4 Sep
349
3945 Sep
194

Last 9 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.04%2 Sep
0.48%
0.16%
0.46%
0.60%3 Sep
1.42%4 Sep
0.00%
0.51%5 Sep
0.00%

Reactions — likes, reposts, replies and quotes — divided by views. Median for under 10K accounts is 1.41%.

What the audience does

Likes59.5%309 in total
Reposts11.9%62 in total
Replies5.4%28 in total
Quotes1.5%8 in total
Bookmarks21.6%112 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Comptes similaires